Janet E Brown - JoVE Visualize

Showing results (31-40 of 60) with videos related to

Pageof 6

Sort By:

Cancers|May 16, 2023

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In VivoLubaid Saleh, Penelope D Ottewell, Janet E Brown, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activityVera Hirsh, Pierre P Major, Allan Lipton, et al.

JBMR Plus|September 22, 2025

ATM inhibition increases the anti-tumor efficacy of radium-223 (Ra-223) against prostate cancer bone metastasis in preclinical modelsDiane V Lefley, Callum G Jones, Jiabao Zhou, et al.

Scientific Reports|March 20, 2025

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate useNataliia Petruk, Steven L Wood, Walter Gregory, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006

Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphomaJanet E Brown, Sue P Ellis, Paul Silcocks, et al.

Diagnostics (Basel, Switzerland)|August 7, 2021

Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell CancerJim Zhong, Ebrahim Palkhi, David L Buckley, et al.

Journal of the National Cancer Institute|January 6, 2005

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJanet E Brown, Richard J Cook, Pierre Major, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acidRobert E Coleman, Pierre Major, Allan Lipton, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2016

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive AgentsAllan Lipton, Matthew R Smith, Karim Fizazi, et al.

Oncology Reports|April 6, 2006

Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumoursDaniele Santini, Bruno Vincenzi, Rosemary A Hannon, et al.

Pageof 6

Showing results (31-40 of 60) with videos related to

Sort By:

Pageof 6

Cancers|May 16, 2023

The CDK4/6 Inhibitor Palbociclib Inhibits Estrogen-Positive and Triple Negative Breast Cancer Bone Metastasis In VivoLubaid Saleh, Penelope D Ottewell, Janet E Brown, et al.

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 5, 2008

Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activityVera Hirsh, Pierre P Major, Allan Lipton, et al.

JBMR Plus|September 22, 2025

ATM inhibition increases the anti-tumor efficacy of radium-223 (Ra-223) against prostate cancer bone metastasis in preclinical modelsDiane V Lefley, Callum G Jones, Jiabao Zhou, et al.

Scientific Reports|March 20, 2025

Increased primary breast tumor expression of CD73 is associated with development of bone metastases and is a potential biomarker for adjuvant bisphosphonate useNataliia Petruk, Steven L Wood, Walter Gregory, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2006

Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphomaJanet E Brown, Sue P Ellis, Paul Silcocks, et al.

Diagnostics (Basel, Switzerland)|August 7, 2021

Feasibility Study on Using Dynamic Contrast Enhanced MRI to Assess the Effect of Tyrosine Kinase Inhibitor Therapy within the STAR Trial of Metastatic Renal Cell CancerJim Zhong, Ebrahim Palkhi, David L Buckley, et al.

Journal of the National Cancer Institute|January 6, 2005

Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumorsJanet E Brown, Richard J Cook, Pierre Major, et al.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 29, 2005

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acidRobert E Coleman, Pierre Major, Allan Lipton, et al.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 4, 2016

Changes in Bone Turnover Marker Levels and Clinical Outcomes in Patients with Advanced Cancer and Bone Metastases Treated with Bone Antiresorptive AgentsAllan Lipton, Matthew R Smith, Karim Fizazi, et al.

Oncology Reports|April 6, 2006

Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumoursDaniele Santini, Bruno Vincenzi, Rosemary A Hannon, et al.

Pageof 6